CLAIMS

1. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a multidoe-type eye drop container, wherein the amount of the aqueous ophthalmic composition to be filled is 1 to 10 mL.

2. The aqueous ophthalmic composition according to claim 1, further comprising a silver salt.

3. The aqueous ophthalmic composition according to claim 2, wherein the silver salt comprises silver nitrate.

4. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

5. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

6. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 1 to 5% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

7. The aqueous ophthalmic composition according to claim 1, comprising diquafosol sodium at a concentration of 3% (w/v) and having a viscosity at 25°C of 1.5 to 30 mPa·s.

8. The aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day.

9. The aqueous ophthalmic composition according to any one of claims 1 to 7, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 3 times a day.

10. The aqueous ophthalmic composition according to claim 8 or 9, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye in a dose of 1 to 2 drops each time.

11. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a multidose-type eye drop container.

12. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 5 mL of an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a multidose-type eye drop container.

13. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a PFMD container.

14. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 5 mL of an aqueous ophthalmic composition comprising diquafosol or a salt thereof and polyvinylpyrrolidone filled in a PFMD container.

15. The ophthalmic medicament product according to any one of claims 11 to 14, wherein the aqueous ophthalmic composition comprises diquafosol sodium at a concentration of 1 to 5% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

16. The ophthalmic medicament product according to any one of claims 11 to 14, wherein the aqueous ophthalmic composition comprises diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

17. The ophthalmic medicament product according to any one of claims 11 to 14, wherein the aqueous composition comprises diquafosol sodium at a concentration of 1 to 5% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

18. The ophthalmic medicament product according to any one of claims 11 to 14, wherein the aqueous composition comprises diquafosol sodium at a concentration of 3% (w/v) and has a viscosity at 25°C of 1.5 to 30 mPa·s.

19. The ophthalmic medicament product according to any one of claims 11 to 18, wherein the ophthalmic medicament product is used so as to be instilled into the eye 2 to 4 times a day.

20. The ophthalmic medicament product according to any one of claims 11 to 18, wherein the ophthalmic medicament product is used so as to be instilled into the eye 3 times a day.

21. The ophthalmic medicament product according to claim 19 or 20, wherein the ophthalmic medicament product is used so as to be instilled into the eye in a dose of 1 to 2 drops each time.

22. The aqueous ophthalmic composition according to any one of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of 17 or more.

23. The aqueous ophthalmic composition according to any one of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of 17 to 120.

24. The aqueous ophthalmic composition according to any one of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of more than 30 and 120 or less.

25. The aqueous ophthalmic composition according to any one of claims 1 to 3, comprising polyvinylpyrrolidone having a K value of 90 or more.

26. The aqueous ophthalmic composition according to any one of claims 1 to 10, wherein the concentration of the polyvinylpyrrolidone is 0.001% (w/v) or more.

27. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the concentration of the diquafosol or a salt thereof is 0.0001 to 10% (w/v).

28. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the concentration of the diquafosol or a salt thereof is 0.01 to 5% (w/v).

29. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the concentration of the diquafosol or a salt thereof is 1 to 5% (w/v).

30. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the concentration of the diquafosol or a salt thereof is 3% (w/v).

31. The aqueous ophthalmic composition according to any one of claims 1 to 10, wherein the aqueous ophthalmic composition has a pH in the range of 6 to 8.

32. The aqueous ophthalmic composition according to any one of claims 1 to 10, wherein the aqueous ophthalmic composition has a pH in the range of 7 to 8.

33. The aqueous ophthalmic composition according to any one of claims 1 to 10, wherein the aqueous ophthalmic composition is a sterile aqueous ophthalmic solution.

34. The aqueous ophthalmic composition according to any one of claims 1 to 10, wherein the aqueous ophthalmic composition is preservable at room temperature.

35. The aqueous ophthalmic composition according to any one of claims 1 to 5, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 1.5 to 30 mPa·s.

36. The aqueous ophthalmic composition according to any one of claims 1 to 3, wherein the salt of diquafosol is diquafosol sodium.

37. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone having a K value of 90, and silver nitrate, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

38. An aqueous ophthalmic composition for prevention or treatment of dry eye, comprising diquafosol sodium at a concentration of 3% (w/v), polyvinylpyrrolidone, and silver nitrate, the aqueous ophthalmic composition being used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s.

39. The aqueous ophthalmic composition according to claim 37 or 38, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 3 times a day.

40. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a multidose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of 90, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

41. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a multidose-type eye drop container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s and is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

42. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a PFMD container, the aqueous ophthalmic composition comprising diquafosol sodium at a concentration of 3% (w/v) and polyvinylpyrrolidone having a K value of 90, wherein the aqueous ophthalmic composition is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

43. An ophthalmic medicament product for prevention or treatment of dry eye, comprising 1 to 10 mL of an aqueous ophthalmic composition filled in a PFMD container, the aqueous ophthalmic composition comprising diquafosol sodium at a

concentration of 3% (w/v) and polyvinylpyrrolidone, wherein the aqueous ophthalmic composition has a viscosity at 25°C of 3 to 30 mPa·s and is used so as to be instilled into the eye 2 to 4 times a day in a dose of 1 or 2 drops each time.

44. The ophthalmic medicament product according to any one of claims 40 to 43, wherein the ophthalmic medicament product is used so as to be instilled into the eye 3 times a day.

45. The ophthalmic medicament product according to any one of claim 40 or 41, further comprising silver nitrate.